director photo

Prof. Peltola

Neurologist at Tampere University Hospital, Finland

Curriculum Vitae

JUKKA PELTOLA
Born 30.1.1960, Tampere, Finland
Tampere University Hospital, Department of neurology, neurosurgery and rehabilitation, PO BOX 2000, 33521 Tampere
Email: Jukka.Peltola@pshp.fi

* Education and Qualifications

2008-present: Docent, University of Tampere
2005: PhD, University of Tampere
1994: Specialist in Neurology, Tampere University Hospital
1988–1994: Resident , Departments of Neurology, Neurophysiology and Medicine, Tampere University Hospital
1986: Licenciate of Medicine (M.D.), University of Tampere

* Professional Experiences

2007–present: Deputy Chief Physician, Department of Neurology, Tampere University Hospital
2000–present: Consultant neurologist, Finnmedi Research
2002–6: Consultant Neurologist, Department of Neurology, Tampere University Hospital
1995–2001: Lecturer in Neurology, University of Tampere
1995: Research fellow, University of Tampere

* Extracurricular Activities

Reviewer of Journals:Acta Neurologica Scandinvica, Annals of Neurology, Epilepsia, Journal of Neuroscience, Journal of Neurochemistry, European Journal of Neurology, Lancet Neurology, Life Sciences, and Epilepsy Research.
Reviewer of Dissertations: 2
Supervisor of Dissertations: 2

* Publications

Number of publications: 81
Publication area: mainly epilepsy, some publications in psychiatry and other subfields of neurology

PUBLICATIONS

1) Korpinen L., Pietilä T., Peltola J., Nissilä M., Keränen T., Tuovinen T., Falck B., Petranek E.S., Frey H.: Evaluation of Epilepsy Expert - a decision support system.Computer Methods and Programs in Biomedicine 1994;45:223-231

2) Korpinen L., Partinen M., Telakivi T., Martikainen K., Pietilä T., Peltola J., Falck B., Frey H.: Evaluation of Sleep Expert - a computer-aided decision support system for sleep disorders. Medical Informatics (Med.Inform.) 1994;19:247-252

3) Peltola J, Hakkarainen K, Marttinen A, Soppi E, Molnar G: Circulating autoantibodies to a 240 kD fetal brain protein. Life Sciences 1996;58(6):519-523

4) Peltola J, Sumelahti ML, Kumpulainen T, Dastidar P,Helen P. Spinal epidural haematoma complicating diagnostic lumbar puncture. Lancet 1996;347;131

5) Keränen T, Peltola J. Epilepsialääkkeiden yhteisvaikutukset. Suomen Lääkärilehti 1996;51(9):897-901

6) Lönnrot K, Metsä-Ketelä T, Molnar G, Ahonen J-P, Latvala M, Peltola J, Pietilä T, Alho H: The effect of ascorbate and ubiquinone supplementation on plasma and csf total antioxidant capacity , Free Radic Biol Med 1996;21(2):211-217

7) Peltola J: MS-taudin lääkehoidon uusi aikakausi. Suomen Lääkärilehti 1996;51(27):2685-2690

8) Keränen T, Peltola J. Lääkepitoisuusmääritykset epilepsian hoidon seurannassa. Suomen Lääkärilehti 1996;51(35):3727-3730

9) Peltola J, Keränen T: Interferon beta in multiple sclerosis -some form of compromise must be accepted. BMJ 1997;314:600

10) Peltola J, Molnar G: Uusia mahdollisuuksia kroonisten immuunineuropatioiden tunnistamisessa ja hoidossa. Duodecim 1997;113:1033-1039

11) Peltola J, Hurme M, Miettinen A, Keränen T: Elevated levels of interleukin-6 may occur in cerebrospinal fluid from patients with recent epileptic seizures. Epilepsy Res 1998;31:129-133

12) Peltola J, Hietaharju A, Rantala I, Lehtinen T, Haapasalo H. A reversible neuronal antibody (anti-Tr) associated paraneoplastic cerebellar degeneration in Hodgkin´s disease Acta Neurol Scand 1998;98:360-363

13) Dastidar P, Heinonen T, Lehtimäki T, Ukkonen M, Peltola J, Erilä T, Laasonen E, Elovaara I: Volumes of plaques and brain atrophy correlated with neurological disability in patients with secondary progressive multiple sclerosis. J Neurol Sci 1999;165:36-42

14) Auvinen A, Peltola J. Oinodootteja ja enoterapiaa- viini lääketieteessä. Duodecim 1999;1152623-2632

15) Elovaara I, Ukkonen M, Leppäkynnäs M, Lehtimäki T, Luomala M, Peltola J, Dastidar P. Adhesion molecules in multiple sclerosis: Relation to subtypes of disease and methylprednisolone therapy Arch Neurol 2000;57:546-551

16) Peltola J, Kulmala P, Isojärvi J, Saiz A, Latvala K, Palmio J, Savola K, Knip M, Keränen T, Graus F: Autoantibodies to glutamic acid decarboxylase in patients with therapy resistant epilepsy. Neurology 2000;55:46-50

17) Peltola J, Palmio J, Korhonen L, Suhonen J, Hurme M, Miettinen A, Lindholm D, Keränen T. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epil Res 2000;41:205-211

18) Murros K, Kataja M, Hedman C, Havanka H, Säkö E, Färkkilä M, Peltola J, Keränen T. Modified release formulation of tizanidine in chronic tension-type headache. Headache 2000;40(8):633-637

19) Peltola J, Keränen T. Epileptisten kohtausten erotusdiagnostiikka ja hoidon aloittaminen. Erikoislääkäri 2000;10(6):1-6

20) Peltola J, Haapala AM, Isojärvi J, Auvinen A, Palmio J, Latvala K, Kulmala P, Laine S, Vaarala O. Anti-phosholipid and antinuclear antibodies in epileptic syndromes and newly onset seizure disorders. Am J Med 2000;109:712-717

21) Palmio J, Peltola J, Vuorio P, Suhonen J, Keränen T. Normal neuron-spesific enolase and S-100 protein levels in patients with recent non-complicated tonic-clonic seizures J Neurol Sci 2001;183(1):27-31

22) Hietaharju A, Peltola J, Seppä J, Luukkainen R, Dastidar P. The coexistence of systemic lupus erythematosus and multiple sclerosis in a mother and a daughter. Scand J Rheumatol 2001;30:120-122

23) Peltola J, Eriksson K, Keränen T. Cytokines and seizures. Arch Neurol 2001;58:1168-69

24) Eriksson K, Peltola J, Haapala A-M, Keränen T, Koivikko M: High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 patients Epilepsy Res 2001;46(2):129-37

25) Peltola J, Hurme M , Rainesalo S, Keränen T. Polymorphisms in IL-1 Gene Complex in Localisation-related Epilepsy. Ann Neurol 2001; 50(2):275-276

26) Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The profile of neuropsychiatric syndromes in systemic lupus erythematosus patients according to the new American College of Rheumatology nomenclature - results from a Finnish population based study. Neurology 2001;57:496-499

27) Peltola J, Ukkonen M, Moilanen E, Elovaara I. Increased nitric oxide production in patients with primary progressive multiple sclerosis. Neurology 2001; 57: 895-96

28) Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Auvinen A. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum (Arthritis Care Res). 2001 Oct;45(5):419-

29) Peltola J,Hellman J, Hakkarainen K, Marttinen A, Soppi E, Molnar GK. Naturally occurring human autoantibodies recognize a fetal brain antigen identified as microtubulus associated protein 1B. Life Sci 2002 70/8:887-8

30) Peltola J, Laaksonen J, Haapala AM, Rainesalo S, Hurme M, Keränen T. Indicators of inflammation after recent tonic-clonic epileptic seizures correlate with plasma interleukin-6 levels. Seizure 2002;11:44-46

31) Kyläniemi M, Haapasalo H, Hietaharju A, Peltola J. Paraneoplastiset neurologiset syndroomat-diagnoosi ja hoito. Duodecim 2002;118:341-7

32) Keränen T, Rainesalo S, Peltola J. The usefulness of video-EEG monitoring in elderly patients with seizure disorders. Seizure 2002;11:269-72

33) Lehtimäki K, Peltola J, Koskikallio E, Keränen T, Honkaniemi J. Expression of cytokines and cytokine receptors after kainic acid induced seizures. Mol Brain Res 2003;110:253-260

34) Loukkola J, Laine M, Ainiala H, Peltola J, Auvinen A, Hietaharju A. Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol 2003;25(1):145-151

35) Rainesalo S, Keränen T, Peltola J, Saransaari P. Glutamate uptake in blood platelets from epileptic patients. Neurochem Int 2003;43:389-392

36) Rainesalo S, Saransaari P, Peltola J, Keränen T. Uptake of GABA and the activity of GABA- transaminase platelets of epileptic patients. Epilepsy Res 2003

37) Rainesalo S, Keränen T, , Palmio J, Peltola J, Oja SS, Saransaari P. Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res 2004; 29;319-324

38) Metsäranta P, Koivikko M, Peltola J, Eriksson K. Outcome after prolonged convulsive seizures in 186 children: low morbidity, no mortality. Dev Med Child Neurol 2004;46:4-8

39) Kyläniemi M,Koskinen M, Karhunen P, Rantala I, Peltola J, Haapasalo: A novel frozen brain tissue array technique: immunohistochemical detection of neuronal paraneoplastic autoantibodies. Neuropathol Appl Neurobiol. 2004;30(1):39-45.

40) Honkaniemi J, Hirvonen K, Udd B, Ala-Hurula V, Oksanen V, Ylä-Sahra R, Hietaharju J, Peltola J. Multifokaalinen motorinen neuropatia. Duodecim 2004;120:50-8

41) Ainiala H, Hietaharju A, Dastidar P, Loukkola J, Lehtimäki T, Peltola J, Korpela M, Heinonen T, Nikkari S. Increased serum matrix metalloproteinase-9 in SLE patients with neuropsychiatric manifestations and brain MRI abnormalities. Arthritis Rheum. 2004;50(3):858-65

42) Ranua J, Luoma K, Peltola J, Haapala AM, Auvinen A, Isojärvi JIT. Anticardiolipin and antinuclear antibodies in adult patients with epilepsy – a population based cross-sectional study. Epil Res 2004;58:13-18

43) Lehtimäki K, Palmio J, Hurme M, Suhonen J, Keränen T, Peltola J. Interleukin-6 family concentrations in CSF and plasma reflect the duration of epileptic seizures. J Neuroimmunol 2004;152:121-125

44) Hulkkonen J, Koskikallio E, Keränen T, Hurme M, Peltola J. The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among epilepsy patientsand healthy control subjects. Epil Res 2004;59:199-205

45) Kalueff A, Lehtimäki K, Ylinen A, Peltola J. Intranasal administration of human recombinant Interleukin-6 increases the severity of ptz-induced seizures. Neurosci Let 2004;365:106-110

46) Rainesalo S, Peltola J, Auvinen A, Keränen T. A retrospective study of 175 patients using oxcarbazepine monotherapy treatment. Seizure 2005;14:72-74

47) Ranua J, Luoma K, Auvinen A, Peltola J, Haapala AM, Raitanen J, Isojärvi J. IgA, IgG and IgM serum concentration in patients with epielepsy and matched controls – a cohort based cross-sectional study. Epilepsy Behav. 2005;6(2):191-5

48) Eriksson K, Peltola J, Kälviäinen R. Kohtausten hoidosta epilepsian hoitoon- tunnista epilepsiaoireyhtymä. Duodecim 2005; 121:505-12

49) Ranua J, Luoma K, Auvinen A, Haapala AM, Mäki M, Peltola J, Raitanen J, Isojärvi J. Celiac disease related antibodies in an epilepsy cohort and matched reference population. Epilepsy Behav 2005;6:388-392

50) Ranua J, Luoma K, Auvinen A, Haapala A-M, Mäki M, Peltola J, Raitanen J, Isojärvi J. Antimitochondrial antibodies in patients with epilepsy . Epilepsy Behav 2005;7:95-97

51) Koskinen M, Kyläniemi M, Peltola J , Rantala I, Hietaharju A, Udd B, Haa¬pasalo H. A simple modified method for diagnostic assessment of intraepidermal nerve fibers in small-fiber neuropathies. J Neurol 2005;252:789-794

52) Ainiala H, Dastidar P, Loukkola J, Lehtimäki T , Korpela M, Peltola J, Heinonen T, Hietaharju A. Computerized volumetric analysis of cerebral MRI lesions in the evaluation of neuropsychiatric systemic lupus erythematosus. Scand J Rheumatol 2005;34:376-382

53) Palmio J, Huuhka M, Saransaari P, Oja S, Peltola J, Leinonen E, Suhonen J, Keränen T. Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatric Res 2005;137:183-190

54) Genton P, Sadzot B, Fejerman N, Peltola J, Despland PA, Steinhoff B, Rektor I, Wroe S, Maubrey MC, Vandervelden C, vn Hammee G, Schlit Af, van Paesschen W. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. Acta Neurol Scnad 2006;113:387-394

55) Honkaniemi J, Kulmala M, Haapasalo H, Peltola J. Paraneoplastiset neurologiset oireyhtymät 261-264. Kirjassa Neuroimmunologia, toim Elovaara et al. Yliopistopaino, Helsinki 2006

56) Lehtimäki K, Keränen, T, Palmio J, Mäkinen R, Hurme M, Honkaniemi J, Peltola J. Increased plasma levels of cytokines after seizures in localization-related epilepsy. Acta Neurol Scand 2007;116:226-230

57) Vezzani A, Peltola J, Janigro D. Inflammation. In Epilepsy; A Comprehensive Textbook, Editors Engel J and Pedley T. Lippincott Williams & Wilkins, Philadelphia. 2008; 267-276

58) Peltola J, Peltola M, Raitanen J, Keränen T, Kharazmi E, Auvinen A. Seizure-freedom with combination therapy in localization-related epilepsy. Seizure 2008;17:276-280

59) Lehtimäki K, Huuhka M, Palmio J, Hurme M, Suhonen J, Keränen T, Peltola J. Interleukin-6 concentrations in plasma reflect the energy of electric shock. J ECT 2008;24:88-91

60) Peltola J, Peltola M, Auvinen A, Keränen T, Liimatainen S, Kharazmi E, Fallah M. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study. Acta Neurol Scand 2008;117:332-336

61) Liimatainen S, Raitanen J, Ylinen M, Peltola M, Peltola J. The Benefit of Active Drug Trials is Dependent on the Aetiology in Refractory Focal Epilepsy. J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):808-12

62) Palmio J, Keränen T, Alapirtti T, Mäkinen R, Peltola J. Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: A video-EEG study. Epilepsy Res. 2008 Oct;81(2-3):155-60.

63) Peltola J, Peltola M, Auvinen A, Raitanen J, Fallah M, Keränen T. Retention rates of new anti-epileptic drugs in refractory localization-related epilepsy: A single-center study. Acta Neurol Scand. 2009 Jan;119(1):55-60.

64) Peltola J, Coetzee C, Jimenez F, Litovchenko T, Sridharan R, Zaslavaskiy L, Lu S, Sykes D. Once-daily extended-release levetiracetam as add-on therapy in patients with refractory partial-onset seizures: a double-blind, randomized, placebo-controlled trial. Epilepsia 2009 Mar;50(3):406-14.

65) Liimatainen S, Peltola M, Fallah M, Kharazmi E, Haapala A-M, Peltola J. The High Prevalence of Antiphospholipid Antibodies in Refractory Focal Epilepsy is Related to Recurrent Seizures. Eur J Neurol. 2009 Jan;16(1):134-41

66) Liimatainen S, Fallah M, Kharazmi E, Peltola M, Peltola J: Interleukin-6 Levels are Increased in Temporal Lobe Epilepsy but not in Extra-Temporal Lobe Epilepsy. J Neurol. 2009 May;256(5):796-802.

67) Lehtimäki K, Keränen T, Palmio J, Rainesalo S, Saransaari P, Peltola J: Regulation of Cerebrospinal Fluid Levels of Cytokines after Seizures: The role of IL-6 and Glutamic acid. Eur J Neurol. 2009 Apr;16(4):e75

68) Alapirtti T, Rinta S, Hulkkonen J, Mäkinen R, Keränen T, Peltola J. Interleukin-6, interleukin-1 receptor antagonist and interleukin-1beta production in patients with focal epilepsy: A video-EEG study. J Neurol Sci. 2009 May 15;280(1-2):94-7.

69) Peltola M, Kaukinen K, Dastidar P, Haimila K, Haapala A, Maki M, Keranen T, Peltola J. Hippocampal sclerosis in refractory temporal lobe epilepsy is associated with gluten sensitivity. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):626-30.

70) Mervaala E, Mäkinen R, Peltola J, Eriksson K, Jutila L, Immonen A. Video-EEG epilepsian diagnostiikassa, milloin, miksi? Duodecim 2009;125(22):2514-20

71) Palmio J, Suhonen J, Keränen T, Hulkkonen J, Peltola J, Pirttilä T. Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure. Seizure. 2009 May 8. [Epub ahead of print]

72) Lehtimäki K, Keränen T, Palmio J, Rainesalo S, Saransaari P, Peltola J. Levels of Il-1beta and IL-1ra in cerebrospinal fluid of human patients after single and prolonged seizures. Neuroimmunomodulation 2010;17(1):19-22. Epub 2009 Oct 5

73) Liimatainen S, Peltola M, Sabater L, Fallah M, Kharazmi E, Haapala AM, Dastidar P, Knip M, Saiz A, Peltola J. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia. 2010 May;51(5):760-7. Epub 2009 Oct 8

74) Kharazmi E, Peltola M, Fallah M, Keränen T, Peltola J. Idiopathic generalized epilepsies: A follow-up study in a single-center. Acta Neurol Scand. 2010 Sep;122(3):196-201. Epub 2009 Nov 16

75) Palmio J, Huuhka M, Laine S, Huhtala H, Peltola J, E. Leinonen E, Suhonen J and Keränen T. Electroconvulsive therapy and biomarkers of neuronal injury and plasticity: serum levels of neuron-specific enolase and S-100b protein. Psychiatry Res. 2010 May 15;177(1-2):97-100. Epub 2010 Apr 8.

76) Lehtimäki K, Peltola J, Liimatainen S, Haapala A, Arvio M. Cardiolipin and Beta2-Glycoprotein-I Antibodies Associate with Cognitive Impairment and Seizure Frequency in Developmental Disorders. Seizure. 2011 Jul;20(6):438-41.

77) Liimatainen S, Lehtimäki K, Raitala A, Peltola M, Oja SS, Peltola J, Hurme MA. Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy. Epilepsy Res. 2011 Mar 3. [Epub ahead of print]

78) Lehtimäki KA, Liimatainen S, Peltola J, Arvio M. The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy. Epilepsy Res. 2011 Jun;95(1-2):184-7.

79) Liimatainen S, Ollikainen J, Peltola J. Non-konvulsiivisen status epilepticuksen hoito. Duodecim. 2011;127(15):1591-6.

80) Alapirtti T, Waris M, Fallah M, Soilu-Hänninen M, Mäkinen R, Kharazmi E, Peltola J. C-reactive protein and seizures in focal epilepsy: A video-electroencephalographic study. In press Epilepsia

81) Liimatainen S, Peltola J. Glutamic acid decarboxylase (GADA) -associated epilepsy. Editorial to Eur J Neurol in press